Economic evaluation of regular transfusions for cerebral infarct recurrence in the Silent Cerebral Infarct Transfusion Trial

• Published in: Blood advances Vol. 5; no. 23; pp. 5032 - 5040
• Main Authors: Hsu, Peter, Gay, James C., Lin, Chyongchiou J., Rodeghier, Mark, DeBaun, Michael R., Cronin, Robert M.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 14.12.2021; American Society of Hematology
• Subjects: Blood Transfusion; Cerebral Infarction - etiology; Cerebral Infarction - therapy; Child; Clinical Trials and Observations; Cost-Benefit Analysis; Humans; Hydroxyurea; Stroke; United States; United States
• ISSN: 2473-9529; 2473-9537
• DOI: 10.1182/bloodadvances.2021004864

In 2020, the American Society of Hematology published evidence-based guidelines for cerebrovascular disease in individuals with sickle cell anemia (SCA). Although the guidelines were based on National Institutes of Health–sponsored randomized controlled trials, no cost-effectiveness analysis was completed for children with SCA and silent cerebral infarcts. We conducted a cost-effectiveness analysis comparing regular blood transfusion vs standard care using SIT (Silent Cerebral Infarct Transfusion) Trial participants. This analysis included a modified societal perspective with direct costs (hospitalization, emergency department visit, transfusion, outpatient care, and iron chelation) and indirect costs (special education). Direct medical costs were estimated from hospitalizations from SIT hospitals and unlinked aggregated hospital and outpatient costs from SIT sites by using the Pediatric Health Information System. Indirect costs were estimated from published literature. Effectiveness was prevention of infarct recurrence. An incremental cost-effectiveness ratio using a 3-year time horizon (mean SIT Trial participant follow-up) compared transfusion vs standard care. A total of 196 participants received transfusions (n = 90) or standard care (n = 106), with a mean age of 10.0 years. Annual hospitalization costs were reduced by 54% for transfusions vs standard care ($4929 vs $10 802), but transfusion group outpatient costs added $22 454 to $137 022 per year. Special education cost savings were $2634 over 3 years for every infarct prevented. Transfusion therapy had an incremental cost-effectiveness ratio of $22 025 per infarct prevented. Children with preexisting silent cerebral infarcts receiving blood transfusions had lower hospitalization costs but higher outpatient costs, primarily associated with the oral iron chelator deferasirox. Regular blood transfusion therapy is cost-effective for infarct recurrence in children with SCA. This trial is registered at www.clinicaltrials.gov as #NCT00072761. •Children with preexisting silent cerebral infarcts on regular transfusion therapy had 50% lower hospitalization costs than standard care.•The incremental cost-effectiveness ratio for transfusion therapy to prevent infarct recurrence was $22 025 for every infarct prevented. [Display omitted]